KaloBios drops CF progam after Phase II miss

KaloBios Pharmaceuticals Inc. (NASDAQ:KBIO) said it would discontinue development of KB001-A in cystic fibrosis after the compound failed a Phase II study in CF patients with Pseudomonas aeruginosa lung infections. The compound missed the primary endpoint of increased time to need for antibiotics for worsening respiratory tract signs and symptoms as well as secondary endpoints of improvements in FEV1 and subject-reported outcomes as measured by Cystic Fibrosis Respiratory Symptom Diary (CFRSD).

Last September, KaloBios regained all rights to the humanized, pegylated antibody fragment against PcrV (V-antigen) on P. aeruginosa from the Sanofi Pasteur S.A. vaccines division of Sanofi (Euronext:SAN; NYSE:SNY). ...